ArticleJournal of gastrointestinal oncology2025
The unique role of cuproptosis in the prognosis and treatment of rectum adenocarcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of cuproptosis in digestive system tumors (Review).International journal of molecular medicine · 2026Review
- A novel cuproptosis-related prognostic gene signature and validation of differential expression in colon cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of digestive system cancers has increased significantly in recent years. Among these, rectum adenocarcinoma (READ), which exhibits distinct features compared to colon adenocarcinoma, has emerged as a unique subtype. Cuproptosis, a recently identified form of non-apoptotic programmed cell death, plays a pivotal role in tumorigenesis; however, its relationship with READ and its potential effect on prognosis remains poorly understood. This study innovatively explores the role of cuproptosis related genes (CRGs) in READ development and identifies potential therapeutic targets. Methods: This study used consensus clustering to classify READ samples into three distinct clusters based on their survival status and enriched biological pathways. A cuproptosis-related score (CRS) was developed to examine the association between cuproptosis subtypes and patient prognosis. Immune infiltration was analyzed using multiple deconvolution algorithms to explore the immune landscape across different cuproptosis subtypes. A principal component analysis (PCA) was conducted to construct a prognostic score that reflects the clinical significance of cuproptosis in READ. Further investigations focused on lipoic acid synthetase (LIAS) as a key gene with prognostic implications for READ patients. Results: Consensus clustering of the READ samples revealed three clusters with varying survival outcomes and distinct biological pathways. The CRS successfully predicted patient prognosis, and was found to be correlated with overall survival (OS) and tumor characteristics. The immune infiltration analysis revealed significant differences in immune profiles across the subtypes, with certain subtypes exhibiting immunosuppressive characteristics. LIAS was identified as a favorable prognostic marker for READ patients, and thus could serve as a potential therapeutic target. Conclusions: CRGs play a critical role in the development and prognosis of READ. The established CRS could serve as a valuable tool for predicting patient outcomes. Further, LIAS emerged as a potential therapeutic target. Our findings may provide new avenues for targeted cancer treatment in READ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.